Quantification of BCR-ABL transcripts in peripheral blood cells and plasma of chronic myeloid leukemia patients at different stages of tyrosine kinase inhibitor treatment response

Choo Yuen Ting, Ahmad Fuad Shamsuddin, Kian Meng Chang, Mohd Makmor Bakry, Norazrina Azmi

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Purpose: To investigate the feasibility of using peripheral blood plasma samples as surrogates for blood cell sampling for quantification of breakpoint cluster region-Abelson oncogene (BCR-ABL) transcript levels to monitor treatment responses in chronic myeloid leukemia (CML) patients. Methods: Peripheral blood samples were collected from 20 healthy individuals and 165 CML patients at various stages of treatment response. Level of BCR-ABL mutation gene transcripts were determined by RNA extraction and quantitative real time polymerase chain reaction (RT-PCR). Results: The ratio of BCR-ABL transcripts/ABL transcripts in blood cells was significantly higher (p < 0.05) than in plasma for untreated and treated patients. Patients who received tyrosine kinase inhibitor (TKI) therapy and achieved major molecular response during treatment had the lowest mean ratio detected in blood cells (0.06 ± 0.0 %) and the ratio was below the detectable limit in plasma samples. Unlike plasma samples, BCR-ABL/ABL transcript ratios in blood cell samples strongly correlated with white cell counts in CML patients undergoing all types of treatment responses. Conclusion: Blood cell sampling is more sensitive than plasma sampling in diagnosis and evaluation of CML treatment response.

Original languageEnglish
Pages (from-to)657-663
Number of pages7
JournalTropical Journal of Pharmaceutical Research
Volume16
Issue number3
DOIs
Publication statusPublished - 1 Mar 2017

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Oncogenes
Protein-Tyrosine Kinases
Blood Cells
Therapeutics
Real-Time Polymerase Chain Reaction
Cell Count
RNA
Mutation
Genes

Keywords

  • Chronic myeloid leukemia
  • Peripheral blood cells
  • Plasma RNA
  • Treatment response
  • Tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Pharmacology (medical)

Cite this

@article{0bbec09ddc104418a47247c5ec53189f,
title = "Quantification of BCR-ABL transcripts in peripheral blood cells and plasma of chronic myeloid leukemia patients at different stages of tyrosine kinase inhibitor treatment response",
abstract = "Purpose: To investigate the feasibility of using peripheral blood plasma samples as surrogates for blood cell sampling for quantification of breakpoint cluster region-Abelson oncogene (BCR-ABL) transcript levels to monitor treatment responses in chronic myeloid leukemia (CML) patients. Methods: Peripheral blood samples were collected from 20 healthy individuals and 165 CML patients at various stages of treatment response. Level of BCR-ABL mutation gene transcripts were determined by RNA extraction and quantitative real time polymerase chain reaction (RT-PCR). Results: The ratio of BCR-ABL transcripts/ABL transcripts in blood cells was significantly higher (p < 0.05) than in plasma for untreated and treated patients. Patients who received tyrosine kinase inhibitor (TKI) therapy and achieved major molecular response during treatment had the lowest mean ratio detected in blood cells (0.06 ± 0.0 {\%}) and the ratio was below the detectable limit in plasma samples. Unlike plasma samples, BCR-ABL/ABL transcript ratios in blood cell samples strongly correlated with white cell counts in CML patients undergoing all types of treatment responses. Conclusion: Blood cell sampling is more sensitive than plasma sampling in diagnosis and evaluation of CML treatment response.",
keywords = "Chronic myeloid leukemia, Peripheral blood cells, Plasma RNA, Treatment response, Tyrosine kinase inhibitors",
author = "Ting, {Choo Yuen} and Shamsuddin, {Ahmad Fuad} and Chang, {Kian Meng} and {Makmor Bakry}, Mohd and Norazrina Azmi",
year = "2017",
month = "3",
day = "1",
doi = "10.4314/tjpr.v16i3.22",
language = "English",
volume = "16",
pages = "657--663",
journal = "Tropical Journal of Pharmaceutical Research",
issn = "1596-5996",
publisher = "Pharmacotherapy Group",
number = "3",

}

TY - JOUR

T1 - Quantification of BCR-ABL transcripts in peripheral blood cells and plasma of chronic myeloid leukemia patients at different stages of tyrosine kinase inhibitor treatment response

AU - Ting, Choo Yuen

AU - Shamsuddin, Ahmad Fuad

AU - Chang, Kian Meng

AU - Makmor Bakry, Mohd

AU - Azmi, Norazrina

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Purpose: To investigate the feasibility of using peripheral blood plasma samples as surrogates for blood cell sampling for quantification of breakpoint cluster region-Abelson oncogene (BCR-ABL) transcript levels to monitor treatment responses in chronic myeloid leukemia (CML) patients. Methods: Peripheral blood samples were collected from 20 healthy individuals and 165 CML patients at various stages of treatment response. Level of BCR-ABL mutation gene transcripts were determined by RNA extraction and quantitative real time polymerase chain reaction (RT-PCR). Results: The ratio of BCR-ABL transcripts/ABL transcripts in blood cells was significantly higher (p < 0.05) than in plasma for untreated and treated patients. Patients who received tyrosine kinase inhibitor (TKI) therapy and achieved major molecular response during treatment had the lowest mean ratio detected in blood cells (0.06 ± 0.0 %) and the ratio was below the detectable limit in plasma samples. Unlike plasma samples, BCR-ABL/ABL transcript ratios in blood cell samples strongly correlated with white cell counts in CML patients undergoing all types of treatment responses. Conclusion: Blood cell sampling is more sensitive than plasma sampling in diagnosis and evaluation of CML treatment response.

AB - Purpose: To investigate the feasibility of using peripheral blood plasma samples as surrogates for blood cell sampling for quantification of breakpoint cluster region-Abelson oncogene (BCR-ABL) transcript levels to monitor treatment responses in chronic myeloid leukemia (CML) patients. Methods: Peripheral blood samples were collected from 20 healthy individuals and 165 CML patients at various stages of treatment response. Level of BCR-ABL mutation gene transcripts were determined by RNA extraction and quantitative real time polymerase chain reaction (RT-PCR). Results: The ratio of BCR-ABL transcripts/ABL transcripts in blood cells was significantly higher (p < 0.05) than in plasma for untreated and treated patients. Patients who received tyrosine kinase inhibitor (TKI) therapy and achieved major molecular response during treatment had the lowest mean ratio detected in blood cells (0.06 ± 0.0 %) and the ratio was below the detectable limit in plasma samples. Unlike plasma samples, BCR-ABL/ABL transcript ratios in blood cell samples strongly correlated with white cell counts in CML patients undergoing all types of treatment responses. Conclusion: Blood cell sampling is more sensitive than plasma sampling in diagnosis and evaluation of CML treatment response.

KW - Chronic myeloid leukemia

KW - Peripheral blood cells

KW - Plasma RNA

KW - Treatment response

KW - Tyrosine kinase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=85016947228&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016947228&partnerID=8YFLogxK

U2 - 10.4314/tjpr.v16i3.22

DO - 10.4314/tjpr.v16i3.22

M3 - Article

VL - 16

SP - 657

EP - 663

JO - Tropical Journal of Pharmaceutical Research

JF - Tropical Journal of Pharmaceutical Research

SN - 1596-5996

IS - 3

ER -